# Clinical and Regulatory Insights on MDMB-4en-PINACA Synthetic Cannabinoid > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/mdmb-4en-pinaca-synthetic-cannabinoid-risks-schedule-i/ > **Published:** 2026-06-16T00:45:54-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:24:03-04:00 > **Clinical Summary:** Explore MDMB-4en-PINACA synthetic cannabinoid risks and its Schedule I classification, highlighting clinical and regulatory implications for healthcare providers. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. βš’ Policy Watch Β |Β  Federal Register cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesMDMB-4en-PINACASchedule_Istate_regulation Clinical Summary The Drug Enforcement Administration has placed MDMB-4en-PINACA, a synthetic cannabinoid, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act, classifying it as having high abuse potential and no accepted medical use. This action addresses the emergence of this novel psychoactive substance in the illicit drug market, where it has been sold as a cannabis substitute and poses significant [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) risks due to its potency and unpredictable effects. For clinicians, this scheduling reinforces the distinction between regulated cannabis products and dangerous synthetic alternatives, which patients may unknowingly encounter in unregulated markets and which can cause severe adverse effects including psychosis, cardiovascular complications, and acute kidney injury. The placement also highlights the ongoing challenge of synthetic cannabinoid proliferation, as manufacturers rapidly modify chemical structures to evade legal restrictions. Clinicians should remain vigilant in screening patients for use of these unregulated substances and educate patients about the risks of purchasing cannabis products from non-licensed sources where synthetic contaminants may be present. Understanding the regulatory landscape around novel [synthetic cannabinoids](https://cedclinic.com/synthetic-cannabinoid-parkinsons-trial-ser-252-funding/) helps clinicians better counsel patients on the relative safety differences between medically supervised cannabis and illicit alternatives. Clinical Perspective 🧠 This [federal scheduling](https://cedclinic.com/investigator-initiated-cannabis-research-barriers/) decision for MDMB-4en-PINACA, a synthetic cannabinoid, reflects ongoing regulatory efforts to address emerging drugs of abuse that circumvent existing controlled substance laws. [Synthetic cannabinoids](https://cedclinic.com/synthetic-cannabinoid-parkinsons-trial-ser-252-funding/) are increasingly encountered in emergency departments and [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/) settings, often causing acute psychiatric symptoms, cardiovascular effects, and seizures that may be more severe than those from cannabis or traditional drugs of abuse. While scheduling serves a regulatory function, clinicians should recognize that it does not prevent drug use and that patients may still encounter these compounds, particularly in regions where enforcement lags or where substitution occurs as variants are prohibited. The complexity here lies in balancing [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) protection through legal restriction with the reality that rapid chemical modification allows manufacturers to create legal analogs faster than regulatory bodies can schedule them. Practically, providers should maintain a high index of suspicion for synthetic cannabinoid toxicity in patients presenting with acute behavioral disturbance, chest pain πŸ’¬ Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan β†’](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion β†’](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+MDMB-4en-PINACA+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F04%2F24%2F2026-08104%2Fschedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F04%2F24%2F2026-08104%2Fschedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i)[πŸ¦… Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+MDMB-4en-PINACA+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F04%2F24%2F2026-08104%2Fschedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i)[πŸ“· Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[πŸ“ Read more on Substack](https://doctorapprovedcannabis.substack.com/)[πŸ”” Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I - Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I - Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I πŸ“° Source: [https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i](https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I Detailed analysis of Schedule I placement for multiple [synthetic cannabinoids](https://cedclinic.com/synthetic-cannabinoid-parkinsons-trial-ser-252-funding/) including 4F-MDMB-BUTICA and ADB-4en-PINACA. Read More [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) Insights into the DEA’s Schedule I classification of the synthetic cannabinoid CUMYL-PEGACLONE and its clinical implications. [Explore Details](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) Review of the temporary Schedule I placement of 2-Fluorodeschloroketamine and its regulatory context. [Learn More](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR Β§ 164.514(b)) and criteria for secondary research exemption under 45 CFR Β§ 46.104(d)(4).